Is solriamfetol approved in Japan for narcolepsy, and when?
Solriamfetol has regulatory status in Japan for sleep-wake disorders, but the exact “narcolepsy approval” timing for 2026 is not specified in the information provided here. To confirm whether Japan approval for narcolepsy happens in 2026 (or already occurred), you typically need the specific Japanese regulator (PMDA) product approval notice and the approved indication text.
What indication matters for “narcolepsy” approvals in Japan?
Narcolepsy approvals are usually tied to an approved indication that may be written as narcolepsy itself and/or excessive daytime sleepiness associated with narcolepsy. If you are tracking “2026 approval,” check whether Japan’s label is for:
- narcolepsy (the condition), or
- excessive daytime sleepiness in narcolepsy, or
- both, plus any related subtypes/criteria.
The difference matters because some wake-promoting drugs are approved for symptom-based targets (like excessive daytime sleepiness) rather than the full diagnostic label.
How to verify a 2026 Japan approval quickly (what to look for)?
For the most reliable confirmation, look up:
- PMDA approval documents for solriamfetol in Japan (often via the PMDA medicines database), and
- the Japanese label/insert that lists the exact approved indications and wording.
These documents will show the approved indication(s) and the approval date (or period), which is what determines whether it is a 2026 event.
Could 2026 “approval” mean something other than first marketing authorization?
Sometimes people refer to “approval” when they mean:
- label expansion (new indication added in 2026),
- reimbursement listing timing,
- distribution start date after approval, or
- approval in a different jurisdiction later (confused date/market).
To avoid a mismatch, verify the actual PMDA approval date and whether the narcolepsy indication is new or already approved.
What you can search next to get the exact answer for Japan + narcolepsy
Try these targeted searches (they usually surface the PMDA page or official label text):
- “PMDA solriamfetol narcolepsy approval date Japan”
- “solriamfetol Japan package insert narcolepsy”
- “Sunosi solriamfetol Japan narcolepsy indication”
If you share the source you’re using (a link, press release text, or the exact label wording you saw), I can help interpret it and determine whether it truly indicates narcolepsy approval in 2026 versus a different kind of update.
Sources
None provided.